Mitsopoulos Efstathios, Pateinakis Panagiotis, Keskinis Christodoulos, Papadopoulou Dorothea
Department of Nephrology, General Hospital of Thessaloniki "Papageorgiou", Thessaloniki, Greece.
Nephron. 2025;149(5):283-287. doi: 10.1159/000543271. Epub 2024 Dec 23.
The combination of nephrotic syndrome with mild histopathological lesions of IgA nephropathy is considered by some as a special form of IgA nephropathy with superimposed minimal change disease (MCD) while by others as a coincidental deposition of IgA in patients with MCD (MCD-IgAN). We present the first case of complete remission of nephrotic syndrome in a 55-year-old man with MCD-IgAN after the administration of a targeted-release formulation of budesonide (TRF-budesonide). The patient's treatment with TRF-budesonide, even though methylprednisolone, mycophenolate mofetil, and cyclophosphamide had been previously tried, is of particular importance because it not only suggests that TRF-budesonide appears to be a promising treatment for MCD-IgAN but may also provide a new therapeutic option for patients with podocytopathies.
肾病综合征与IgA肾病轻度组织病理学病变的组合，一些人认为是IgA肾病合并微小病变病（MCD）的一种特殊形式，而另一些人则认为是MCD患者中IgA的偶然沉积（MCD-IgAN）。我们报告了首例55岁MCD-IgAN男性患者在使用布地奈德靶向释放制剂（TRF-布地奈德）后肾病综合征完全缓解的病例。该患者使用TRF-布地奈德进行治疗，尽管之前曾尝试使用甲基泼尼松龙、霉酚酸酯和环磷酰胺，但该治疗尤为重要，因为它不仅表明TRF-布地奈德似乎是治疗MCD-IgAN的一种有前景的疗法，而且可能为足细胞病患者提供一种新的治疗选择。
